Immunoregulatory plasma lipoproteins. Role of apoprotein E and apoprotein B
- PMID: 7440569
Immunoregulatory plasma lipoproteins. Role of apoprotein E and apoprotein B
Abstract
Plasma lipoproteins containing either the B (apo-B) or E (apo-E) apoproteins, e.g. apo-B low density lipoproteins (LDL) isolated from normolipemic humans and apo-E-containing cholesterol-induced high density lipoproteins (apo-E HDLc) isolated from cholesterol-fed dogs, suppress phytohemagglutinin (PHA)-induced lymphocyte activation and inhibit early events such as mitogen-enhanced 45Ca2+ accumulation and late events such as enhanced DNA synthesis. On a molar basis, apo-E HDLc are 3.5 times more effective than apo-B LDL in inhibiting 45Ca2+ accumulation by 50% and 3.8 times more effective than apo-B LDL in suppressing DNA synthesis by 50%. Both lipoproteins bind to the lymphocyte surface, and in competitive binding assays apo-E HDLc and apo-B LDL bind to the same receptors. These receptors, termed immunoregulatory receptors, comprise a homogeneous class of binding sites which do not act cooperatively. The equilibrium dissociation constant (Kd) for apo-B LDL is 2.0 X 10(-7) M at 4 degrees C and 37 degrees C; the Kd for apo-E HDLc is 9.3 X 10(-8) M at 4 degrees C and 7.3 X 10(-8) M at 37 degrees C. At saturation, 16,000 and 20,000 LDL particles are bound/cell at 4 degrees C and 37 degrees C, respectively. The corresponding values for apo-E HDLc are 6,700 at 4 degrees C and 5,500 at 37 degrees C. The increased effectiveness of apo-E HDLc in supp]ressing the PHA-induced Ca2+ accumulation and DNA synthesis is due to the multiple receptor binding of apo-E HDLc. At 37 degrees C, each apo-E HDLc particle occupies multiple receptors at a ratio of 3.6:1 relative to apo-B LDL. The enhanced affinity of apo-E HDLc most likely results from the multiple interactions of this lipoprotein with the receptors.
Similar articles
-
Lipoprotein binding to canine hepatic membranes. Metabolically distinct apo-E and apo-B,E receptors.J Biol Chem. 1981 Jun 10;256(11):5646-55. J Biol Chem. 1981. PMID: 6263887
-
Rate and equilibrium constants for binding of apo-E HDLc (a cholesterol-induced lipoprotein) and low density lipoproteins to human fibroblasts: evidence for multiple receptor binding of apo-E HDLc.Proc Natl Acad Sci U S A. 1979 May;76(5):2311-5. doi: 10.1073/pnas.76.5.2311. Proc Natl Acad Sci U S A. 1979. PMID: 221921 Free PMC article.
-
Functional unit of the low density lipoprotein receptor of fibroblasts: a 100,000-dalton structure with multiple binding sites.Proc Natl Acad Sci U S A. 1981 Jul;78(7):4378-82. doi: 10.1073/pnas.78.7.4378. Proc Natl Acad Sci U S A. 1981. PMID: 6270675 Free PMC article.
-
Receptor interactions controlling lipoprotein metabolism.Can J Biochem Cell Biol. 1985 Aug;63(8):898-905. doi: 10.1139/o85-111. Can J Biochem Cell Biol. 1985. PMID: 2998579 Review.
-
Expression of LDL receptor binding determinants in very low density lipoproteins.Ann N Y Acad Sci. 1985;454:239-47. doi: 10.1111/j.1749-6632.1985.tb11863.x. Ann N Y Acad Sci. 1985. PMID: 3907464 Review.
Cited by
-
The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms.EMBO J. 1986 Dec 20;5(13):3495-507. doi: 10.1002/j.1460-2075.1986.tb04675.x. EMBO J. 1986. PMID: 3030729 Free PMC article.
-
Granzyme B degrades extracellular matrix and contributes to delayed wound closure in apolipoprotein E knockout mice.Cell Death Differ. 2013 Oct;20(10):1404-14. doi: 10.1038/cdd.2013.96. Epub 2013 Aug 2. Cell Death Differ. 2013. PMID: 23912712 Free PMC article.
-
Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells.Proc Natl Acad Sci U S A. 1992 May 15;89(10):4471-5. doi: 10.1073/pnas.89.10.4471. Proc Natl Acad Sci U S A. 1992. PMID: 1584779 Free PMC article.
-
Heterogeneous expression of apolipoprotein-E by human macrophages.Immunology. 2004 Nov;113(3):338-47. doi: 10.1111/j.1365-2567.2004.01972.x. Immunology. 2004. PMID: 15500620 Free PMC article.
-
CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.Immunotherapy. 2017 Sep;9(11):929-941. doi: 10.2217/imt-2017-0056. Immunotherapy. 2017. PMID: 29338610 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous